- Home
- STSS vs HSDT Comparison
STSS vs HSDT Comparison
Compare STSS & HSDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STSS
- HSDT
- Stock Information
- Founded
- STSS 2017
- HSDT 2014
- Country
- STSS United States
- HSDT United States
- Employees
- STSS N/A
- HSDT N/A
- Industry
- STSS Medical/Dental Instruments
- HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- STSS Health Care
- HSDT Health Care
- Exchange
- STSS Nasdaq
- HSDT Nasdaq
- Market Cap
- STSS 3.3M
- HSDT 2.9M
- IPO Year
- STSS 2022
- HSDT N/A
- Fundamental
- Price
- STSS $0.37
- HSDT $0.41
- Analyst Decision
- STSS
- HSDT Hold
- Analyst Count
- STSS 0
- HSDT 1
- Target Price
- STSS N/A
- HSDT N/A
- AVG Volume (30 Days)
- STSS 41.3M
- HSDT 202.0K
- Earning Date
- STSS 03-31-2025
- HSDT 05-12-2025
- Dividend Yield
- STSS N/A
- HSDT N/A
- EPS Growth
- STSS N/A
- HSDT N/A
- EPS
- STSS N/A
- HSDT N/A
- Revenue
- STSS N/A
- HSDT $502,000.00
- Revenue This Year
- STSS N/A
- HSDT N/A
- Revenue Next Year
- STSS N/A
- HSDT $8.97
- P/E Ratio
- STSS N/A
- HSDT N/A
- Revenue Growth
- STSS N/A
- HSDT N/A
- 52 Week Low
- STSS $0.25
- HSDT $0.37
- 52 Week High
- STSS $18.15
- HSDT $7.19
- Technical
- Relative Strength Index (RSI)
- STSS 42.15
- HSDT 35.66
- Support Level
- STSS $0.28
- HSDT $0.41
- Resistance Level
- STSS $0.70
- HSDT $0.47
- Average True Range (ATR)
- STSS 0.08
- HSDT 0.05
- MACD
- STSS 0.06
- HSDT -0.00
- Stochastic Oscillator
- STSS 26.32
- HSDT 6.79
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes are designed to eliminate potentially infectious and accidental needlestick injuries.
About HSDT Helius Medical Technologies Inc. (DE)
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.